Arch Therapeutics (ARTH) Stock Price, News & Analysis

Company Overview

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Key Stats

• Today's Range: $0.20 to $0.20
• 50-Day Range: $0.16 to $0.27
• 52-Week Range: $0.16 to $1.57
• Volume: N/A
• Average Volume: 4,151 shs
• Market Capitalization: $948,400.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARTH Stock Analysis - Frequently Asked Questions

How have ARTH shares performed this year?

Arch Therapeutics' stock was trading at $0.17 on January 1st, 2025. Since then, ARTH stock has increased by 17.6% and is now trading at $0.20.
View the best growth stocks for 2025 here.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) posted its quarterly earnings results on Thursday, July, 23rd. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01.

How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arch Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), Adobe (ADBE), General Electric (GE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 7/23/2020
• Today: 4/21/2025
• Next Earnings (Estimated): 4/25/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:ARTH
• Previous Symbol: NASDAQ:ARTH
• CIK: 1537561
• Web: www.archtherapeutics.com
• Phone: (617) 431-2313
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,980,000.00
• Net Margins: -8,257.70%
• Pretax Margin: -8,257.70%
• Return on Equity: N/A
• Return on Assets: -730.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.10
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: $80,000.00
• Price / Sales: 11.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.43) per share
• Price / Book: -0.08

Miscellaneous

• Outstanding Shares: 4,742,000
• Free Float: 4,529,000
• Market Cap: $948,400.00
• Optionable: Not Optionable
• Beta: 4.02